Veracyte (VCYT) Stock Price, News & Analysis

Company Overview

Veracyte, Inc. is a diagnostic company that develops and commercializes genomic tests designed to help physicians diagnose cancer, assess disease risk and guide treatment decisions. Its tests analyze genetic information from patient samples and are intended to provide more precise answers than traditional diagnostic methods alone.

The company’s portfolio includes Afirma genomic tests for thyroid nodules, Decipher tests for prostate cancer, Percepta tests for lung cancer and Envisio tests that support the evaluation of certain lung nodules. Veracyte also offers CancerTYPE ID, a molecular test designed to help identify the tissue of origin for difficult-to-diagnose cancers. The company expanded its capabilities in spatial biology and breast cancer testing through its acquisition of NanoString Technologies, which added products including the Prosigna breast cancer assay and spatial biology platforms.

Founded in 2008 and headquartered in South San Francisco, California, Veracyte serves healthcare providers, laboratories and patients primarily in the United States, with certain products and services available internationally through regulatory approvals and commercial relationships. The company is led by President and Chief Executive Officer Marc Stapley.

Key Stats

• Today's Range: $44.09 to $48.84
• 50-Day Range: $38.50 to $59.78
• 52-Week Range: $29.45 to $60.91
• Volume: 1.01 million shs
• Average Volume: 1.14 million shs
• Market Capitalization: $3.58 billion
• P/E Ratio: 31.65
• Dividend Yield: N/A
• Price Target: $55.78
• Consensus Rating: Moderate Buy

Veracyte Stock Analysis - MarketRank™

Veracyte scored higher than 82% of companies evaluated by MarketBeat, and ranked 153rd out of 885 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Veracyte has received a consensus rating of Moderate Buy. The company's average rating score is 2.64, and is based on 1 strong buy rating, 6 buy ratings, 3 hold ratings, and 1 sell rating.

Upside Potential

Veracyte has a consensus price target of $55.78, representing about 25.7% upside from its current price of $44.39.

Amount of Analyst Coverage

Veracyte has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 3.1 / 5
• Proj. Earnings Growth: 16.67%

Earnings Growth

Earnings for Veracyte are expected to grow by 16.67% in the coming year, from $1.32 to $1.54 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Veracyte is 31.35, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 44.70.

Price to Earnings Ratio vs. Sector

The P/E ratio of Veracyte is 31.35, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 274.31.

Price to Book Value per Share Ratio

Veracyte has a P/B Ratio of 2.68. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

10.62% of the float of Veracyte has been sold short.

Short Interest Ratio / Days to Cover

Veracyte has a short interest ratio ("days to cover") of 7.76.

Change versus previous month

Short interest in Veracyte has recently increased by 4.04%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Veracyte does not currently pay a dividend.

Dividend Growth

Veracyte does not have a long track record of dividend growth.

News and Social Media

• Score: 2.5 / 5
• News Sentiment: -0.05

News Sentiment

Veracyte has a news sentiment score of -0.05. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.41 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 6 news articles for Veracyte this week, compared to 4 articles on an average week.

Search Interest

16 people have searched for VCYT on MarketBeat in the last 30 days. This is an increase of 433% compared to the previous 30 days.

MarketBeat Follows

3 people have added Veracyte to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Veracyte insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,307,448.00 in company stock.

Percentage Held by Insiders

1.60% of the stock of Veracyte is held by insiders.

Percentage Held by Institutions

Veracyte has minimal institutional ownership at this time.

Company Calendar

• Last Earnings: 7/30/2026
• Today: 10/06/2026
• Next Earnings (Estimated): 11/03/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:VCYT
• CIK: 1384101
• Web: www.veracyte.com
• Phone: (650) 243-6300
• Fax: 650-243-6301
• Employees: 755
• Year Founded: 2008

Price Target and Rating

• Average Price Target for Veracyte: $55.78
• High Price Target: $69.00
• Low Price Target: $44.00
• Potential Upside/Downside: +25.7%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.64
• Research Coverage: 11 Analysts

Profitability

• EPS (Trailing Twelve Months): $1.41
• Trailing P/E Ratio: 31.35
• Forward P/E Ratio: 33.63
• P/E Growth: N/A
• Net Income: $66.35 million
• Net Margins: 20.37%
• Pretax Margin: 20.65%
• Return on Equity: 9.26%
• Return on Assets: 8.61%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 9.16
• Quick Ratio: 8.80

Sales & Book Value

• Annual Sales: $561.90 million
• Price / Sales: 6.35
• Cash Flow: $1.44 per share
• Price / Cash Flow: 30.75
• Book Value: $16.57 per share
• Price / Book: 2.68

Miscellaneous

• Outstanding Shares: 80,391,000
• Free Float: 79,105,000
• Market Cap: $3.57 billion
• Optionable: Optionable
• Beta: 1.95